Introduction
The von Hippel-Lindau tumor suppressor, E3 ubiquitin protein ligase (VHL) gene [GenBank:
NG_008212. 3, OMIM# 193300] , is a tumor suppressor gene which spans a 14.25-kb genomic region at 3p25.3. It encodes for 2 alternatively spliced transcript variants. Transcript variant 1 (NM_000551.3) which is encoded by all 3 exons is translated to a protein with 213 amino acid residues (NP_000542.1) while transcript variant 2 (NM_198156.2) is translated to a protein with 172 acid residues (NP_937799.1) [1] .
Mutations in the VHL tumor suppresser gene cause a variety of phenotypes including von
Hippel-Lindau disease (VHL), familial phaeochromocytoma and inherited polycythaemia [2] . VHL is an autosomal dominantly inherited familial cancer syndrome predisposing to a variety of malignant and benign tumors [3] such as haemangioblastomas of the cerebellum, spinal cord, brainstem and retina, clear cell renal carcinomas, pheochromocytomas, endolymphatic sac tumours, pancreatic islet cell tumours, haemangiomas of the adrenals, liver and lungs, epididymal and broad ligament papillary cyst adenomas as well as visceral cysts in the kidneys and pancreas [4] . A germline mutation of the VHL gene is the basis of familial inheritance of VHL syndrome. According to Knudson's ("Two Hit") hypothesis, both alleles of a tumor suppresser gene need to be mutated in order for a tumour to develop, therefore a patient who manifests a tumour, inherits one mutation from a parent, and develops the second mutation in the same gene in the affected organ as a somatic mutation, at which point the tumour begins to manifest [5] .
To date, more than 300 mutations have been identified in families with VHL disease, consisting of partial and whole gene deletions, frameshift, nonsense, missense, and splice site mutations [6] . About 20% of cases are due to de novo mutations. This report describes a Sri Lankan family with 3 siblings with cerebellar haemangioblastoma due to a heterozygous nonsense mutation in the VHL gene.
The Family
A 28 year old female that was clinically diagnosed with cerebellar hemangioblastoma was referred to the Human Genetics Unit for genetic evaluation. The patient was clinically diagnosed with cerebellar haemangioblastoma at the age of 13 years, since then, she had undergone four surgeries for removal of the recurrent tumour in the posterior cranial fossa. In addition, a tumor arising from the fourth ventricle of the brain was also surgically removed.
Two of her male siblings were also diagnosed with cerebellar hemangioblastoma. The CT scan of one of the brothers showed dilatation and a cystic mass in the lateral third ventricle as well as a renal cyst. Figure 1 shows the pedigree of the family with VHL disease.
Materials and Methods
The VHL gene was sequenced in the patient and her 2 siblings after obtaining their written informed consent. DNA was extracted from peripheral blood using QIAamp blood DNA midi kit from Qiagen. All 3 exons and flanking intronic regions of the VHL gene were sequenced using an ABI PRISM 3130 Genetic Analyzer. The published human VHL gene Reference Sequence file obtained from GenBank (http://www.ncbi.nlm.nih.gov) was used for comparison of the nucleotide sequences generated from the patients and to confirm the presence of any mutations.
Results
A heterozygous nonsense mutation was identified in all 3 individuals in exon 3 of the VHL gene. A single nucleotide substitution at position 13214 (NG_008212. 3.g13214C>G) replaced the codon for amino acid tyrosine (UAC) in transcript variant 1 (NM_000551.3.c525C>G) to a stop codon (UAG) resulting in premature termination of the VHL protein at amino acid position 175 (NP_000542.1.pTyr175Ter). This mutation has previously been reported in other families and documented in the dbSNP database and assigned the SNPID rs5030835 (http://www.ncbi.nlm.nih.gov/projects/SNP/rs=5030835). 
Discussion
This report describes a Sri Lankan family with 3 siblings with cerebellar haemangioblastoma due to a heterozygous nonsense mutation in the VHL gene. VHL mutations are associated with various benign and malignant tumours resulting in high morbidity and mortality rates.
Mutations in the VHL gene are known to cause haemangioblastomas of the central nervous system (CNS) in 60-80% of VHL patients [6, 7] .
A study conducted by van der Harst et al. in 1998 reported that 8 out 68 patients with pheochromocytoma had mutations in the VHL gene. Among these patients, two were relatives and had a familial mutation [8] . Familial mutations in the VHL gene have also been reported in VHL families presenting with clear cell renal cell carcinoma. Recent advances in understanding the genetic basis of VHL disease has resulted in improved diagnosis of VHL disease and provided greater insights into the molecular pathogenesis of the disease [1] . The prognosis can be improved through early screening, diagnosis and surveillance [9] . Molecular genetic testing coupled with genetic counseling is now considered standard for the evaluation of patients and families with suspected VHL [10] .
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PHARMACOGENOMICS REPORT DESIGN AND IMPLEMENTATION OF A NEW ASSAY FOR GENOTYPING
PHARMOCOGENOMICALY
IMPORTANT CYTOCHROME P450 2D6 GENE VARIANTS.
Introduction
In the human population there is a vast variability to drug response among different individuals which is always connected with drug safety and efficacy. Different reasons such as environmental factors, physiologic factors, drug-drug interactions and genetic factors play an important role in this phenomenon. These genetic factors are involved in polymorphism in genes related to drug metabolizers, drug transporters and drug receptors [1] .
"Pharmocogenetics" is the study of how different genetic variants like Single Nucleotide Polymorphisms and Copy Number Variants(SNPs &CNVs) in particular gene effects the drug response [2] .
CYP2D6 gene is located on chromosome 22q13.1 and consists of 4.2 kb region [1] .
Cytochrome P450 2D6 (CYP2D6) is a highly polymorphic gene, which is responsible for the metabolism of several important endogenous substrates and other xenobiotics [3] .Human cytochrome P450 is a gene supper family which contains 57 genes and 58 pseudogenes. Out of which, CYP2D6, CYP2C19, and CYP2C9 play a crutial role in pharmocogenomics since in the present day, 80% of the prescribed drugs are being metabolized by these enzymes [2] .
In this study we have selected CYP2D6 gene since it metabolizes around 25% of the currently used drugs worldwide [4] . This gene contains around 82 allelic variants important in the context of pharmacogenomics [3] .There is a wide difference in the distribution among different ethnic groups. CYP2D6 is responsible for metabolizing antidepressants, antipsychotics, antiarrhythmics, antiemetics, beta-adrenoceptor antagonists (beta-blockers) and opioids. The presence of SNPs alters the CYP2D6 enzymatic activity with effects ranging significantly within a population and includes individuals with ultrarapid (UM), extensive (EM), intermediate (IM), and poor (PM) metabolizer status [3] . The response to the drug may vary depending on the fact that whether the enzyme converts the drug in to the active form or whether the enzyme converts the active form of the drug in to the inactive form [4] .
Most of the times CYP2D6 genotypes are depicted by using a star (*) eg: -CYP2D6 * 1. Each allele / haplotype can be identified using a specific combination of SNPs and/or other sequence variants (deletions, duplications) within the CYP2D6 gene [5] . More than 130
SNPs have been identified within the CYP2D6 gene [3] .In this study we use 9 SNPs (Table.1), which will allow us to identify CYP2D6 alleles in our population [1] .
Currently, different molecular genetic techniques have been employed to genotype CYP2D6 gene variants, including Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP) and allele specific PCR methods. Multiplex single base primer extension technique is a well-documented method developed for genotyping CYP2D6 gene [1] . In this study we attempted to develop a comparatively less expensive new multiplex allele specific PCR method to genotype the above given variants.
Materials and methods
Genomic DNA was obtained from an already existing population-based DNA collection maintained in our unit for studies of this nature with the approval of the Ethics Review Committee of the Faculty of Medicine, University of Colombo. Eighteen allele specific PCR primers for normal alleles (CYP2D6NPs) and mutated alleles (CYP2D6MPs) of all nine SNPs with another nine common reveres primers (CYP2D6RPs) were designed. In the majority of the allele specific primers, additional mismatches were introduced at the 3rd base from the 3' end of the primer to increase their efficacy. 
Initially, the allele specific primers were separated into two master mixtures (MN and MM).
MN mixture contained all the normal allele while MM mixture contained all the mutated allele specific primers. In the final 25 µL reaction tube, concentration of each primer was 0.2 µM, 1X PCR buffer, 3mM MgCl2,50µM each dNTPs and 0.04U/µL Taq DNA polymerase.
Following conditions were defined for the PCR amplification;
Initial denaturation -94 0 C -5 mins
Annealing -60 0 C -30seconds 35cycles
Extension-72 0 C -45seconds
The PCR products were visualized in a 3% agarose gel. However, it was hard to distinguish between 1846G>A (203bp) and 1661G>C (193bp) due to the poor band separation.
Therefore, primers were separated in to four master mixtures (MN1, MM1, MN2, MM2).The relevant reverse primers were also added to the master mixtures respectively (MN1- 
CYP2D6RP4, CYP2D6RP7, CYP2D6RP8).
The final 25 µL reaction mixture consisted of 0.5 µM of each primer, 1X PCR buffer, 3mM
MgCl2,50µM each dNTPs and 0.04U/µL Taq DNA polymerase. 2 µL of the genomic DNA was added each reaction mixtures separately. PCR tubes were labeled as N1, M1, N2, and M2 accordingly. Amplification of desired product were carried out in applied bio system 2720 thermal cycler with following conditions, Initial denaturation -94 C -5 min.
Denaturation -94 C -30 seconds
Annealing -60 C -30 seconds 35cycles
Extension-72 C -45 seconds
Final extension -72 -7 min.
The PCR products were separated by electrophoresis on a 3% agarose gel impregnated with ethidium bromide for 1 hour at 65V and visualized under UV light.
Results
Interpretations of results were achieved by the presents or absence of the bands on the gel.
The bands which represent the PCR product of N1 and N2 mixtures (mixtures with normal allele specific primers) in the gel indicates the presence of normal alleles and the bands which represent M1 and M2 PCR products indicates the presence of mutated allele. If both bands (mutated and normal) were present, the sample was considered as heterozygous for the respective SNP. Bands were observed in lanes 3 and 5, indicating the presence of normal alleles and the absence of all bands in the 4th and the 6th lanes indicate the absence of the mutated alleles for all tested SNPs. All the tested samples were found to be homozygous for normal alleles of all the tested SNPs.
All SNP locations of sample 1 were sequenced to validate the results. Sequences were read with capillary electrophoresis on an ABI 3130 Genetic Analyzer (Applied Biosystems).
Sequence results confirmed the results of allele specific PCR, hence validating the assay
Discussion
The diversity of the CYP2D6 gene is very high within a population than among different populations. Recent studies revealed high frequency of null and low activity variants in certain areas of the world. Distribution patterns of these variants among different populations were more similar to distribution patterns of neutral markers. Depending on the presence or absence of these SNP variants they can be grouped in to various haplotypes as shown below [6] . 
CYP2D6 plays a crucial role in metabolizing antidepressant drugs. Therefore, pharmocogenomic testing should be appropriately combined with the clinical practice in order to get better results. Furthermore, phromocogenomic data should be utilized at the correct moment to improve the patient outcome. Thus, the dosage of the drug should be determined accordingly [7] .
There are several very efficient high throughput SNP genotyping methods currently in use, nevertheless, these methods require specialized probes, chemicals and instrument which are highly expensive hence, unaffordable to the public. These reasons lead to the limitation of the use of these methods in clinical diagnosis. Concurrently, traditional PCR-RFLP methods are laborious and time consuming [8] . Therefore, a solution for above predicament was to design a multiplex allele specific PCR assay.
Multiplex allele specific PCR technique provides an opportunity to amplify many targeted product simultaneously, with several drawbacks .Thus, a complex optimization process is required to enhance the assay. Additionally, the increase number of primer sets reduces the efficiency and flexibility of amplification of desired products [9] .
Therefore, the current assay was optimized by a very complex and tedious optimization process. The only limitation with this method is its low consistency.
Conclusion
Multiplex Allele specific PCR method is a comparatively cost effective method for genotyping CYP2D6 variants nevertheless, this method require further optimization to increase the consistency and reproducibility. 
Limitations:
Not all variants with known impact on enzyme expression and activity are tested in this assay.
Testing Methodology: DNA amplification is done by allele specific multiplex PCR and the analyzing of PCR products is done by agarose gel electrophoresis. Requisition must accompany specimen. Prior to any genetic testing we request that the subject sign our consent form and submit it with the sample. To receive our forms, additional information, please contact to our unite. 
Turnout time: 2 weeks
MOLECULAR CYTOGENETICS REPORT
MOLECULAR-CYTOGENETIC ANALYSIS OF A RING CHROMOSOME
IN A SRI LANKAN FEMALE CHILD WITH CONGENITAL MALFORMATION, HEART DEFECTS AND GLOBAL DEVELOPMENT DELAY Introduction
Ring chromosome 18, (r18) is a rare chromosomal disorder [1] .It can be formed when a part of one or both ends of chromosome 18 has been deleted and joined together [2] . As a result, clinical features of patients with ring chromosome 18 depends on the extent of the deleted region at the chromosomal ends [3] .Clinical features of ring chromosome 18 may include facial dysmorphism, blepharoptosis, hypotonia, development delay, short stature, microcephaly, mental retardation, heart defect and IgA deficiency [1, 3, 4] . Association of global development delay, congenital malformation and heart defects with ring chromosome 18 has been reported in previous studies [4] Ring chromosome 18 can also arise without any deletions due to dysfunctional telomeres [5] .This may lead to asymptomatic carriers of ring chromosome 18.
We report cytogenetic and molecular-cytogenetic findings of a Sri Lankan female child with congenital malformation, heart defects and global development delay.
Case presentation
A two year old girl with congenital malformation, heart Defects and global development delay was referred to the Human Genetics Unit for karyotyping. She is the second child born to a non consanguineous healthy couple at term by a normal delivery following an uneventful pregnancy. The first child of this family is a healthy boy and the second pregnancy ended up in a spontaneous miscarriage at 10 weeks of gestation.
She had a birth weight of 2.2kg,a head circumference of 32 cm and length of 50 cm. She had severe developmental delay and hypotonia. Only partial head control has been achieved at the time of presentation. Social smile was present. She had severe growth failure.
At the age of 2 years her weight was 4.5 kg, head circumference was 39.5 cm and the length was 59 cm. All parameters were well below the 3 rd centile. Apart from dysmorphic features such as microcephaly, flat occiput, mid face hypoplasia and micrognathia were also present.
She had telecanthus, epicanthic folds and slightly up slanted palpebral fissures. Her nasal bridge was flat and ears were marginally low set. Except for long tapering fingers there was no other deformity in the upper limbs but in lower limbs bilateral talipes equinovarus deformity was noted. Appearance of her external genitalia was normal and she did not have any thoracic or spinal abnormalities. Furthermore, ultra sound scan of the abdomen was found to be normal and CT scan of the brain did not identify any structural malformation of the brain.
Materials and Methods
Ethical clearance for the study was obtained from the Ethics review committee of Faculty of Medicine, University of Colombo. Patient was recruited for this study after obtaining the written informed consent from the parents.
Cytogenetic analysis
Peripheral blood of the patient and her parents were cultured in PB-MAX karyotyping media separately for 72 hour. Peripheral blood lymphocytes were harvested and chromosomal staining was carried out with GTL banding technique according to standard protocols.
Metaphase chromosome spreads were analyzed under Olympus BX61 microscope and analyzed using Cytovision 3.1.
FISH analysis
Fish probes RP11-317F19 (specific for GLAR1 gene at 18q23 position) and RP11-1082M21
(specific for TGIF 1 gene at 18p11.3) were ordered from Empire Genomics, USA after studying about the probable genes causing the phenotype. Slide was cleaned with 70%
ethanol. Slide preparation and hybridization of probes were carried out according to standard FISH protocol of Empire Genomics (http://www.empiregenomics.com/resources/genomic_procedures).
Slide preparation from harvested cell suspension carried out with 50% relative humidity.
After air drying the slide, it was kept at 45 0 C in the incubator and then 10 µL of probe mixture (2 µL of the probe and 8 µL of hybrid buffer) was added to the slide. Cover slip was applied on the slide and sealed with rubber cement. Slide was placed in the Thermobrite.
Denatured at 73 0 C for 2 minutes and hybridized for 16 hours. After hybridization cover slip was removed and the slide was washed by agitating with prewarmed WS1 (wash solution 1)
at 73 0 C for 10 seconds and incubated for 2minutes in the solution. Slide was transferred to WS2 at room temperature for 1minutes then it was dried in the dark and 10 µL of DAPPI was added. Again another cover slip was applied on the slide. After 30 minutes fluorescent signals were observed under Olympus BX61 and analysis was done using Applied Spectral Imaging system software. Above procedures were carried separately for both probes.
Results
Twenty six metaphase chromosomal spreads of the patient were analyzed and six of these spreads were karyotyped. Ring chromosome 18 was observed in all the spreads analyzed.
Karyotypes of the parents were found to be normal.
When FISH probe RP11-317F19 (specific for GLAR1 gene at 18q23) position was used, Green fluorescent signals were only seen in normal chromosome 18 and no signal was 
Discussion
The patients with ring chromosome 18 show a wide range of phenotypic features [1] . Majority of the patients reported with ring chromosome 18 shows symptoms of 18q-syndrome while the others show symptoms of 18p-syndrome symptoms or both 18q-and 18p-syndromes [4] .Mental retardation, development delay, heart defects and facial dysmorphism was reported with many cases of ring chromosome 18 [4, 6] .
Stankiewicz et al carried out a clinical and molecular cytogenetic study in 7 patients with ring chromosome 18. In that study they even found a patient mosaic for ring chromosome 18 and another patient with a duplication in 18p arm with mild phenotypes [4] . Table 1 compares the prominent phenotypes of 5 patients of the above study with our patient excluding the patient with mosaic ring chromosome 18. Previous studies had suggested that growth hormone insufficiency is associated with the haploinsufficiency at 18q23 position and GLAR 1 gene(also known as GALNR1) is known to play a role in this phenomena [7] . This explains the deletion of GLAR1 gene in the ring chromosome 18 of our patient FISH probe RP11-1082M21 which is specific for TGIF 1 gene at 18p11.3, had signals in both normal and ring chromosome 18. This result shows the presence of TGIF 1 gene in both ring and normal chromosome, but it does not exclude any possibilities of a deletion distal to the location of TGIF gene.
TGIF 1 Gene (also known as HPE4) at 18p11.3 is found to be associated with holoprosencephaly which is associated with abnormal development of the forebrain and midface [8] . Further FISH analysis with more probes and molecular studies can be employed to determine the exact break points of ring chromosome 18 of this patient.
